Perspective Therapeutics (NYSE:CATX) Earns “Buy” Rating from HC Wainwright

Perspective Therapeutics (NYSE:CATX)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 301.61% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on CATX. Oppenheimer lowered their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $24.00 to $5.00 in a research report on Monday, November 25th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Finally, Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. One analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Buy” and an average target price of $14.56.

Perspective Therapeutics Stock Performance

Shares of Perspective Therapeutics stock opened at $2.49 on Wednesday. Perspective Therapeutics has a 52-week low of $2.32 and a 52-week high of $19.05. The stock’s 50-day simple moving average is $3.05 and its 200 day simple moving average is $6.96.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd bought a new position in shares of Perspective Therapeutics in the fourth quarter worth approximately $33,000. Intech Investment Management LLC bought a new position in shares of Perspective Therapeutics in the third quarter worth approximately $137,000. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics in the fourth quarter worth approximately $34,000. National Bank of Canada FI increased its position in shares of Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after purchasing an additional 10,998 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Perspective Therapeutics in the third quarter worth approximately $152,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.